Form 8-K - Current report:
SEC Accession No. 0001171843-25-005181
Filing Date
2025-08-07
Accepted
2025-08-07 16:02:50
Documents
14
Period of Report
2025-08-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_080625.htm   iXBRL 8-K 15303
2 PRESS RELEASE exh_991.htm EX-99.1 59280
  Complete submission text file 0001171843-25-005181.txt   280976

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20250101.xsd EX-101.SCH 3402
4 XBRL DEFINITION FILE gnw-20250101_def.xml EX-101.DEF 26066
5 XBRL LABEL FILE gnw-20250101_lab.xml EX-101.LAB 35956
6 XBRL PRESENTATION FILE gnw-20250101_pre.xml EX-101.PRE 24702
16 EXTRACTED XBRL INSTANCE DOCUMENT f8k_080625_htm.xml XML 3336
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-15006 | Film No.: 251193791
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)